APRIL 2017 Deal Watch Review now published.
Catharine worked for Medius for five years between 2002 and 2007 and rejoined the team in 2016. Over the last 30 years her career has spanned three areas of expertise within the pharmaceutical industry: finance, business development and consulting. At Medius she supports clients in various aspects of business development training, particularly in product forecasting, the financial structuring of licensing deals and training business development executives in aspects of finance.
Catharine gained her financial experience as a sell-side analyst covering European biotechnology and pharmaceutical stocks at Robert Fleming (now part of JP Morgan), and her business development experience at Medeva and Antisoma. She has also spent 12 years as a health care consultant, initially at The Wilkerson Group in New York and London, and subsequently at Bionest Partners, in New York and Paris, where she advised clients in a wide variety of projects, including new product sales forecasting, strategy, deal analysis and due diligence.
Catharine holds a degree in Natural Sciences (with Part II Genetics) from the University of Cambridge and a MBA from INSEAD in France. She speaks excellent French